Publication | Closed Access

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer

Metastatic Breast CancerBreast OncologyMedicinePharmacologyLocally RecurrentBreast CancerPharmacotherapy2-Methoxyestradiol AloneCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer